Merck Basic Shares Outstanding 2012-2026 | MRK
Merck annual/quarterly basic shares outstanding history and growth rate from 2012 to 2026. Basic shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares.
- Merck basic shares outstanding for the quarter ending March 31, 2026 were $0M, a 100% decline year-over-year.
- Merck basic shares outstanding for the twelve months ending March 31, 2026 were $5.005B, a 50.56% decline year-over-year.
- Merck annual basic shares outstanding for 2025 were $0B, a 100% decline from 2024.
- Merck annual basic shares outstanding for 2024 were $2.532B, a 0.2% decline from 2023.
- Merck annual basic shares outstanding for 2023 were $2.537B, a 0.2% increase from 2022.
|
Merck Annual Basic Shares Outstanding (Millions of US $) |
|
|---|---|
| 2025 | |
| 2024 | $2,532 |
| 2023 | $2,537 |
| 2022 | $2,532 |
| 2021 | $2,530 |
| 2020 | $2,530 |
| 2019 | $2,565 |
| 2018 | $2,664 |
| 2017 | $2,730 |
| 2016 | $2,766 |
| 2015 | $2,816 |
| 2014 | $2,894 |
| 2013 | $2,963 |
| 2012 | $3,041 |
| 2011 | $3,071 |
|
Merck Quarterly Basic Shares Outstanding (Millions of US $) |
|
|---|---|
| 2026-03-31 | |
| 2025-12-31 | |
| 2025-09-30 | $2,495 |
| 2025-06-30 | $2,510 |
| 2025-03-31 | $2,523 |
| 2024-12-31 | $2,532 |
| 2024-09-30 | $2,534 |
| 2024-06-30 | $2,534 |
| 2024-03-31 | $2,533 |
| 2023-12-31 | $2,537 |
| 2023-09-30 | $2,537 |
| 2023-06-30 | $2,539 |
| 2023-03-31 | $2,538 |
| 2022-12-31 | $2,532 |
| 2022-09-30 | $2,533 |
| 2022-06-30 | $2,531 |
| 2022-03-31 | $2,528 |
| 2021-12-31 | $2,530 |
| 2021-09-30 | $2,530 |
| 2021-06-30 | $2,533 |
| 2021-03-31 | $2,531 |
| 2020-12-31 | $2,530 |
| 2020-09-30 | $2,529 |
| 2020-06-30 | $2,527 |
| 2020-03-31 | $2,533 |
| 2019-12-31 | $2,565 |
| 2019-09-30 | $2,558 |
| 2019-06-30 | $2,574 |
| 2019-03-31 | $2,585 |
| 2018-12-31 | $2,664 |
| 2018-09-30 | $2,662 |
| 2018-06-30 | $2,683 |
| 2018-03-31 | $2,695 |
| 2017-12-31 | $2,730 |
| 2017-09-30 | $2,727 |
| 2017-06-30 | $2,734 |
| 2017-03-31 | $2,745 |
| 2016-12-31 | $2,766 |
| 2016-09-30 | $2,765 |
| 2016-06-30 | $2,768 |
| 2016-03-31 | $2,774 |
| 2015-12-31 | $2,816 |
| 2015-09-30 | $2,814 |
| 2015-06-30 | $2,826 |
| 2015-03-31 | $2,835 |
| 2014-12-31 | $2,894 |
| 2014-09-30 | $2,879 |
| 2014-06-30 | $2,917 |
| 2014-03-31 | $2,934 |
| 2013-12-31 | $2,963 |
| 2013-09-30 | $2,927 |
| 2013-06-30 | $2,977 |
| 2013-03-31 | $3,022 |
| 2012-12-31 | $3,041 |
| 2012-09-30 | $3,045 |
| 2012-06-30 | $3,041 |
| 2012-03-31 | $3,043 |
| 2011-12-31 | $3,071 |
| 2011-09-30 | $3,070 |
| 2011-06-30 | $3,086 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $299.893B | $65.011B |
| Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |